ClinicalTrials.gg
RecruitingNCT05892744Re-EMBARCUpdated May 1, 2026

Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression

A Phase 4 interventional study of Sertraline in Major Depressive Disorder and Chronic Major Depression, Recurrent, sponsored by University of Texas at Austin. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University of Texas at Austin · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies testing sertraline in Depressive Disorder, Major — 6 open to participants now, 7 under way, none of them phase 3. Sertraline · Depressive Disorder, Major.

Planned enrollment
27th of 44
50 · median 78
Started
2023
the only one that year
Phase 4
16 of 44
3 open now
Registered
38th of 44
by date

Among the 44 studies testing sertraline in Depressive Disorder, Major, this one is the 27th largest by planned enrollment, is the only one that started in 2023, is one of 16 in phase 4, and was the 38th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

6 of the 44 studies testing sertraline in Depressive Disorder, Major are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About sertraline

Sertraline: first FDA approval 1991 (ZOLOFT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing sertraline in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.

Read the detailed description

Our prior published studies found that sertraline outcome was predicted by biomarkers, primarily in frontoparietal control (FPCN), default mode (DMN), and ventral attention networks (VAN), from different single-modality neuroimaging data, including fMRI activation during emotional conflict regulation, resting EEG power signature, and resting fMRI connectivity. Our recent study with resting EEG connectivity defined two sertraline-predictive subtypes that showed convergent validity between EEG and fMRI. Therefore, the investigators hypothesize that modality-specific regional activity/connections in these networks exhibit similar subject-wise covariation that will jointly predict sertraline treatment response more precisely than either modality alone. However, the derivation of multimodal biomarkers remains highly challenging and underexplored for treatment selection in depression. The overall objective of this proposal is to establish multimodal brain biomarkers using data-driven analytics for treatment selection in depression. With multimodal data from EMBARC, a large publicly-available dataset, the investigators will devise advanced machine learning models to probe brain biomarkers jointly from multiple feature modalities including resting connectivity, task fMRI activation, and EEG band power. An independent cohort will be collected at Dell Medical School, The University of Texas at Austin (UT Austin) with methodology matching that utilized in the EMBARC study to produce a new sample of participants with independent data to validate these biomarker findings. To this end, the investigators will utilize an integrative analysis of both fMRI and EEG to: 1) identify moderators of sertraline versus placebo response in MDD; 2) quantify brain signatures that predict antidepressant treatment outcome; 3) recruit 50 depressed patients, non-invasively assess brain function with a combination of task and resting state fMRI and EEG prior to treatment initiation, administer/prescribe the common antidepressant medication, sertraline (tradename Zoloft), track symptom response over time, and utilize these data as an independent new cohort to optimize and validate brain biomarkers.

Aim 1: Identify multimodal brain moderators of antidepressant treatment effects of sertraline medication in major depressive disorder (MDD) using an existing, publicly-available database (EMBARC). Task 1.1: Using the EMBARC dataset, the investigators will design a canonical correlation analysis-based method to integrate fMRI and EEG to extract region-wise combined brain features. Task 1.2: The investigators will use linear mixed-effect models in a full intent-to-treat framework with the combined features to identify moderators of sertraline versus placebo. Task 1.3: The investigators will compare the statistical strength of the moderators identified between using multimodal features and each single-modality features, reveal neurobiological mechanisms underlying the multimodal moderators, and interpret their associations with depression-relevant clinical symptoms. This aim is crucial to establish novel multimodal brain moderators that can guide treatment selection in depression from a group-level perspective.

Aim 2: Quantify multimodal brain signatures that predict individual antidepressant treatment response to sertraline treatment in MDD using an existing, publicly-available database. Task 2.1: The Investigators will characterize multimodal brain signatures predictive of individual treatment outcomes using a machine learning tool that incorporates predictive modeling into our well-established latent space model with subtype guidance defined in our prior study. Task 2.2: The Investigators will compare multimodal signatures with single-modality and non-biological factors to confirm their efficacy in treatment outcome prediction and demonstrate their transferability to using EEG alone in clinical practice. Task 2.3: The investigators will investigate which brain regions/connections of different modalities are most critical to delineating the multimodal signatures by examining their associations with single-modality features, and interpret the neurocircuitry models in depression underlying the treatment response. These tasks are necessary for developing multimodal signatures of individual responses to antidepressant treatment for personalized medicine.

Aim 3: Optimize and validate multimodal brain biomarkers using new data collected in an independent, open-label clinical trial of sertraline treatment for MDD. Task 3.1: The investigators will recruit 50 individuals with MDD as an independent cohort and will adopt the EMBARC protocol design, including fMRI and EEG assessments at baseline followed by sertraline prescribed to these patients with clinical assessment of outcomes over 8 weeks. Task 3.2: The investigators will refine the multimodal brain signatures using an adaptive optimization strategy with the samples collected each year. Task 3.3: The investigators will perform an extensive validation using the new cohort to verify the multimodal biomarkers discovered in Aims 1-2. This aim will optimize our biomarker findings and provide strong evidence for their generalizability and reproducibility.

This project will establish informative multimodal biomarkers that can moderate clinical effects and predict individual responses to sertraline treatment, thereby providing a promising new avenue towards one of the first implementations in psychiatry of an objective test to inform treatment selection decisions. Our central hypothesis is that modality-specific regional brain activity/connections in FPCN, DMN, and VAN exhibit similar subject-wise covariation that can jointly predict sertraline treatment response more precisely than either modality alone.

03

Conditions studied

  • Major Depressive Disorder
  • Chronic Major Depression, Recurrent

Keywords

  • Depression
  • Chronic Depression
  • Major Depression
  • Recurrent Depression
  • antidepressant
  • sertraline
  • fMRI
  • EEG
  • biomarker
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English as primary language, and comprehension suitable to understand experimenter instructions
  • Meet criteria for a current major depressive episode diagnosed through the Structured Clinical Interview for the 5th edition (DSM-5) (SCID-5)
  • Meet criteria for early onset (prior to age 30) of depression and either: a) current major depressive episode lasts for > 2 years; or b) participant meets criteria for recurrent major depression as evidenced by 2 or more major depressive episodes (including current episode) in their lifetime. These criteria will be assessed by the SCID-5.
  • Have a Quick Inventory of Depression Symptomology Self-Report Measures (QIDS) score > 14 at baseline and the week prior to first Sertraline administration
  • Willing and able to undergo MRI and EEG procedures.

Exclusion criteria

Exclusion Criteria:

  • Non-early onset (i.e., after age 30), non-chronic (current episode lasting less than 2 years or only one lifetime major depressive episode, including current episode) qualifying Major Depressive Disorder
  • Must not have failed to respond to any prior antidepressant treatment in the current episode of sufficient duration and dose as defined by the Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire
  • Currently pregnant, planning to become pregnant, or breastfeeding
  • Evidence of current or prior history of psychosis or bipolar disorder as evidenced by self-report or clinical interview
  • Meeting criteria for a substance-use disorder of moderate or greater severity in the past 6 months
  • Unstable psychiatric or medical conditions that may require hospitalizations or contraindicate study medication (i.e. autism spectrum disorder, schizophrenia, cancer, congestive heart failure, etc.)
  • to MRI including, but not limited to, history of stroke, brain tumors, brain hemorrhages, internal wires, electrodes, pacemakers, implants, irremovable ferromagnetic objects in head that are unsafe for MRI and/or cause large distortions in imaging data, etc.
  • History of epilepsy, moderate or severe traumatic brain injury, penetrating head injury, brain surgery, brain tumors, or any condition requiring an anticonvulsant
  • Treatment with electroconvulsive therapy, vagus nerve stimulation, or transcranial magnetic stimulation during the current depressive episode
  • Concomitant medication use that are likely to interfere or obscure effects from the study medication, including but not limited to antipsychotics and mood stabilizers
  • Current regular depression-specific evidence-based psychotherapy treatment
  • Considered by the investigative team to be a significant suicide risk as evidence by self-report or clinical interview
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    Sertraline hydrochloride, up to 200mg/day or maximum tolerable dose

    Established FDA-approved treatment for major depressive disorder

    Drug: Sertraline

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline on the GRID Hamilton Depression Rating Scale (GRID-HAM-D) at 8 weeks

    Standardized clinician-administered measure of depression symptom severity. Scores range from 0-52. Lower scores indicate less depressive symptomatology, and so are the more desirable.

    Time frame: 8 weeks

Secondary outcomes

  1. Change from Baseline on the Quick Inventory of Depressive Symptomology-Self Report (QIDS-SR) at 8 weeks

    Self-report measure of depressive symptom severity. Scores range from 0 to 27.

    Time frame: 8 weeks

  2. Change from Baseline on the Columbia-Suicide Severity Rating Scale (C-SSRS) at 8 weeks

    Clinician-administered measure of suicidal ideation. Scores range from 0 to 25.

    Time frame: 8 weeks

  3. Change from Baseline on the Beck Anxiety Inventory (BAI) at 8 weeks

    Self-report measure of anxiety symptom severity. Scores range from 0 to 63.

    Time frame: 8 weeks

  4. Change from Baseline on the Spielberger State Trait Anxiety Inventory-Trait Form (STAI-T) at 8 weeks

    Self-report measure of trait anxiety. Scores range from 20 to 80.

    Time frame: 8 weeks

  5. Change from baseline on the Anger Attacks Questionnaire (AAQ) at 8 weeks

    Self-report measure of anger outbursts. Scores range from 5-25.

    Time frame: 8 weeks

  6. Change from baseline on the Irritability domain of the Concise Associated Symptom Tracking Scale-Self Report at 8 weeks

    Self-report measure of irritability. Scores range from 17 to 85.

    Time frame: 8 weeks

  7. Change from baseline on the Snaith-Hamilton Pleasure Scale (SHAPS) at 8 weeks

    Self-report measure of anhedonia. Scores range from 0 to 14.

    Time frame: 8 weeks

  8. Change from baseline on the Patient Health Questionnaire for depression (PHQ-9) at 8 weeks

    Self-report measure of depressive symptom severity. Scores range from 0 to 27.

    Time frame: 8 weeks

  9. Change from baseline on the General Anxiety Disorder (GAD-7) at 8 weeks

    Self-report measure of generalized anxiety disorder symptoms. Scores range from 0 to 21.

    Time frame: 8 weeks

  10. Change from baseline on the Mood and Anxiety Symptom Questionnaire-30 at 8 weeks (MASQ-30)

    Self-report measure of general distress related to anxiety and depression. Scores range from 10 to 50.

    Time frame: 8 weeks

  11. Change from baseline on the Standardized Assessment of Personality-Abbreviated Scale (SAPAS) at 8 weeks

    Assessment of personality. Scores range from 0 to 8.

    Time frame: 8 weeks

  12. Change from baseline on the Clinical Global Impressions Scale (CGI) at 8 weeks

    Clinician-rated measure of global symptom severity. Scores range from 1 to 7.

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Jul 2027, 45 months after the start.

Of 79 non-industry phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 45 months is close to that.

Counting every sponsor, half of 98 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2023
First posted
Jun 7, 2023
StartActual
Sep 30, 2023
Primary completionEst.
Jul 15, 2027
CompletionEst.
Jul 15, 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05892744
Collaborators
Lehigh University
Responsible party
Greg Fonzo (Assistant Professor, University of Texas at Austin) — Principal investigator
First posted
Jun 7, 2023
Start date
Sep 30, 2023
Primary completion
Jul 15, 2027 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
May 1, 2026

Study contacts

Greg Fonzo, Ph.D.
Contact
fonzolab@austin.utexas.edu
512-495-5856
Lauren Enten, B.S.A
Contact
lauren.enten@austin.utexas.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sertraline

Start the discussion